An independent intelligence board aggregating credible research, preprints, clinical findings, biohacking experiments, and community discussions on therapeutic peptides, longevity science, and evidence-based anti-aging. Stories are scored for relevance, credibility, novelty, momentum, and practicality so the most important findings surface first.
Clinics and online sellers are increasingly offering experimental peptide treatments for people with Long COVID (the set of lingering symptoms some people have after a COVID-19 infection). The ads promise fixes for fatigue, brain fog, and other long-term problems, but there’s a gap between what’s being sold and what solid science actually shows. In short: people are being marketed novel peptides before researchers have proven they work for Long COVID. Peptides are short chains of amino acids — think of them as tiny pieces of proteins. Some peptides act like signals in the body and can nudge cells to behave a certain way. A few approved drugs are peptide-based, and some mimics of natural hormones (for example, the class that includes drugs like semaglutide) have known effects. But many of the experimental peptides being advertised for Long COVID are unproven: they’re not established medicines and often come from small companies or compounding pharmacies that promote them based on early lab studies or theory rather than large clinical trials. What the evidence actually shows is limited. Most of the claims for peptides in Long COVID are based on very small studies, anecdotes, or lab work in cells and animals. There are few, if any, large randomized controlled trials showing that these peptides improve the main symptoms of Long COVID in humans. When human data exist, it’s often from tiny groups without a proper comparison to a placebo, which makes it hard to separate real benefits from the placebo effect or natural recovery over time. In short, scientific support is thin and preliminary. Why this matters is practical. Long COVID affects many people and can be debilitating, so there’s a real urge to try treatments that might help. People desperate for relief may spend a lot of money and time on peptide treatments that haven’t been proven safe or effective. That can delay more established care, cause financial strain, or expose patients to unnecessary risk. Clinicians, patients, and policymakers need reliable studies before these treatments become routine. There are important caveats and risks. Experimental peptides may have side effects that aren’t fully known because they haven’t gone through rigorous testing. Quality control can be inconsistent when products come from compounding pharmacies or unregulated online sources. Some people — for example, pregnant people or those with certain medical conditions — could face particular harms, and interactions with other medications are not always studied. Regulatory status varies: some peptides are legal to prescribe off-label, while others are wholly unapproved for human use. Always be cautious of clinics promising quick fixes and ask whether a proposed treatment has shown benefits in well-designed human trials. Bottom line: Experimental peptides for Long COVID are being marketed before solid evidence exists, so approach them with skepticism and consult a trusted clinician and the latest research before trying them.
Source: The Sick Times